(Q83656106)

English

Natalizumab for moderate to severe Crohn's disease in clinical practice: the Mayo Clinic Rochester experience

scientific article published on 14 March 2012

In more languages
default values for all languages
No label defined

No description defined

Statements

Natalizumab for moderate to severe Crohn's disease in clinical practice: the Mayo Clinic Rochester experience (English)

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit